TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30047223
Drug: Threshold-low-glucose-suspend (TLGS)
Normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold-low-glucose-suspend (TLGS) insulin pump delivery
Study: 21862166
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and Sulphonylureas
Study: 17124817
Drug: Wound bed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound bed preparation
Study: 14531593
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 1.5 mol/L aqueous solution of CaCl2 followed by 1.0 mol/L aqueous K3PO4
Study: 14531593
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 1.0 mol/L aqueous solution of KCl followed by distilled water
Study: 11003455
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg/day for 3 days)
Study: 8840843
Drug: Fish oils
Normalized name: fish oils
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oils (5.4 g n‐3 fatty acids)
Study: 8840843
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (30 mg SC BID)
Study: 1309968
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of ASA
Study: 6851195
Drug: Oestrogen-progestagen oral
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen-progestagen oral contraceptives
Study: 29288740
Drug: Enhanced standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced standard treatment plus non-contingent contingency management (EST)
Study: 21746974
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (ET) for type 1 ROP
Study: 21746974
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (ET) for type 2 ROP
Study: 11762556
Drug: Omapatrilat 10
Normalized name: OMAPATRILAT
DrugBank: Omapatrilat (DB00886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat 10 mg on days 6 to 10 and 25 mg on days 11 to 15 with furosemide 20 mg
Study: 11762556
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with furosemide 20 mg
Study: 23415190
Drug: Family-centered, primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-centered, primary care-based intervention involving 6 weeks of interactive group classes followed by 6 months of culturally sensitive monthly coaching
Study: 19544679
Drug: CYP3A4-metabolized statins
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP3A4-metabolized statins (atorvastatin)
Study: 15871555
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (NovoLog, NovoRapid)
Study: 15871555
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart or BIAsp30
Study: 10933570
Drug: Irbesartan 75
Normalized name: irbesartan 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 75 to 300 mg
Study: 10933570
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 to 150 mg
Study: 10535718
Drug: celiprolol 200
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celiprolol 200 mg
Study: 7901342
Drug: Paclitaxel high
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel high dose (175 mg/m2)
Study: 7901342
Drug: Paclitaxel low
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel low dose (135 mg/m2)
Study: 7901342
Drug: Paclitaxel 3-hour
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 3-hour infusion schedule
Study: 7901342
Drug: Paclitaxel 24-hour
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 24-hour infusion schedule
Study: 7901342
Drug: Paclitaxel (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (all treatment arms)
Study: 26951702
Drug: Clopidogrel administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administration directly from the cardiology unit at each monitoring visit
Study: 26951702
Drug: Standard retail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard retail pharmacy channel prescription
Study: 25016276
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) and General exercises
Study: 22430920
Drug: Colchicine (1.0–2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1.0–2.0 mg on the first day, followed by 0.5–1.0 mg/day for 6 months)
Study: 19633042
Drug: High-dose adecatumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adecatumumab (6 mg/kg every two weeks)
Study: 19633042
Drug: Low-dose adecatumumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adecatumumab (2 mg/kg every two weeks)
Study: 19633042
Drug: High-dose adecatumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adecatumumab
Study: 19633042
Drug: Low-dose adecatumumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adecatumumab
Study: 18493207
Drug: Esomeprazole 10
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 10 mg (for children >=20 kg)
Study: 18493207
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg (for children >=20 kg)
Study: 15201942
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day IL-1ra
Study: 8679463
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (5-fluorouracil, doxorubicin, cyclophosphamide)
Study: 3913726
Drug: Fenoprofen calcium
Normalized name: Fenoprofen Calcium
DrugBank: Fenoprofen (DB00573)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenoprofen calcium (doses between 12.5 and 300 mg)
Study: 3913726
Drug: Codeine sulfate
Normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine sulfate (60 mg)
Study: 23106157
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of 1.5 mL (250 MU) of BTX‐A
Study: 22296885
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (OMACOR fish oil, 850-882 mg eicosapentaenoic and docosahexaenoic acid)
Study: 21434529
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN‐alpha2a) 5 MU/m2 to 10 MU/m2 for six months and lamivudine (4 mg/kg/day)
Study: 15755593
Drug: MeNZB™ vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MeNZB™ vaccine
Study: 12126287
Drug: Bupropion for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion for smoking cessation (exact dosage and duration not specified)
Study: 8523110
Drug: 125I-chimeric 17-1A
Normalized name: fibrinogen (125I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125I-chimeric 17-1A antibody, administered in doses of 20, 40, 60, 80, 100, 150, 200, or 250 mCi, with infusions at 4-day intervals.
Study: 1842236
Drug: Butter and
Normalized name: Suave Gentle Body Wash Cocoa Butter and Shea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butter and milk diet (300 mg cholesterol and 95 g fat)
Study: 1842236
Drug: Single egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single egg diet (300 mg cholesterol and 6 g fat)
Study: 1842236
Drug: Crystalline cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalline cholesterol with 200 ml milk (1020 mg cholesterol and 14 g fat)
Study: 31778630
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (6 mL/kg predicted body weight)
Study: 31778630
Drug: Conventional tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tidal volume (10 mL/kg predicted body weight)
Study: 29701662
Drug: Probiotic drink
Normalized name: CVS Probiotic Drink Mix 10 Billion CFU Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic drink containing 10 billion Lactobacillus casei, administered as two bottles daily via feeding tube.
Study: 22920991
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Care (brief advice to quit smoking, nicotine replacement therapy, self-help materials)
Study: 20207829
Drug: Conventional weight‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional weight‐based GH dosing of 40 microg/kg x d (Conv)
Study: 11893636
Drug: Iodixanol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol (150 mgI ml(‐1) and 320 mgI ml(‐1))
Study: 11893636
Drug: Iohexol (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol (140 mgI ml(‐1) and 300 mgI ml(‐1))
Study: 9527073
Drug: Beta blockers,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers, calcium antagonists, or nitrates
Study: 467056
Drug: Paper formulation
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper formulation of oral contraceptive
Study: 455981
Drug: Conventional tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tablet
Study: 27967294
Drug: Myeloid growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloid growth factors (GF) administered to 256 patients (49%)
Study: 27967294
Drug: CHOP or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP or R‐CHOP treatment
Study: 19267286
Drug: Water drinking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water drinking at a rate of 10 ml/min
Study: 19267286
Drug: Nutrient liquid
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient liquid drinking at a rate of 100 ml/min
Study: 19267286
Drug: Nutrient liquid
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient liquid drinking at a rate of 20 ml/min
Study: 12439363
Drug: Preprocedural hydration,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprocedural hydration, amount of dye administered, and postprocedural therapies
Study: 2850682
Drug: Captopril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (mean daily dose: 56 +/- 2 mg)
Study: 2850682
Drug: Enalapril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (mean daily dose: 9.6 +/- 0.9 mg)
Study: 29878501
Drug: 8-mg/day doxazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg/day doxazosin
Study: 29878501
Drug: Doxazosin (4-mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (4-mg/day and 8-mg/day)
Study: 29878501
Drug: Doxazosin (8-mg/day)
Normalized name: doxazosin 8 MG
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxazosin (8-mg/day)
Study: 27167378
Drug: Routine directly-observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine directly-observed anti-TB therapy
Study: 26189139
Drug: Secondary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary treatment with α1-blockers for 8 weeks
Study: 23784467
Drug: Dietary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary therapy of qi-yin-reinforcing porridge
Study: 21155047
Drug: Single-injection femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection femoral nerve block with 0.25% levobupivacaine (30 mL) combined with epidural analgesia
Study: 15646486
Drug: Nyolol Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nyolol Gel 0,1%
Study: 15646486
Drug: Regular timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Regular timolol treatment (Ofterisin 0,5%)
Study: 15646486
Drug: Timolol 0,1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0,1% gel formulation
Study: 8216503
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (1 g t.d.s.)
Study: 3301913
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine gluconate mouthwash used 3 times daily
Study: 22651572
Drug: Standard GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard GH dose (43 μg/kg/day)
Study: 22651572
Drug: Individualized GH
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized GH dose (17‐100 μg/kg/day)
Study: 19924675
Drug: Test dexchlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test dexchlorpheniramine 2.0 mg tablet (Eurofarma)
Study: 19924675
Drug: Reference dexchlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference dexchlorpheniramine 2.0 mg tablet (Celestamine, Schering‐Plough)
Study: 18577692
Drug: Lower insulinemic-euglycemic
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower insulinemic-euglycemic clamp (100 pmol/l insulin, 5 mmol/l glucose)
Study: 18577692
Drug: Hyperinsulinemic-euglycemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic-euglycemic clamp (400 pmol/l insulin, 5 mmol/l glucose)
Study: 18577692
Drug: Lower insulinemic-hyperglycemic
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower insulinemic-hyperglycemic clamp (100 pmol/l insulin, 12 mmol/l glucose)
Study: 18577692
Drug: Hyperinsulinemic-hyperglycemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic-hyperglycemic clamp (400 pmol/l insulin, 12 mmol/l glucose)
Study: 11889391
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (50 microg/100 mL, two puffs for each nostril once daily)
Study: 11889391
Drug: Oxymetazoline (0.05%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline (0.05%, one puff for each nostril three times daily)
Study: 11889391
Drug: 3% Sodium
Normalized name: Dextrose 5% and 0.3% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% Sodium chloride (NaCl, buffered to pH 6.5‐7, given three times daily)
Study: 11889391
Drug: 0.9% Sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium chloride (NaCl, 10-mL solutions for nasal irrigations three times daily)
Study: 11889391
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical treatment (control group)
Study: 9698957
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive pressure ventilation (CPPV) plus surfactant (50 mg/kg body weight)
Study: 30999596
Drug: Meal Replacement
Normalized name: Diabetic meal replacement bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal Replacement (MRP; 70% fat) consumed once daily for eight weeks
Study: 19230048
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: rabeprazole 10 mg + amoxicillin 1 g + furazolidone 100 mg + bismuth subcitrate 220 mg, twice daily for 1 week
Study: 19230048
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: same regimen as Group B, but furazolidone was replaced by furazolidone 100 mg three times daily
Study: 17784949
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g lactulose daily for 4 months
Study: 17784949
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication alone
Study: 11838823
Drug: Adjunctive haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive haloperidol
Study: 3263812
Drug: Propofol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (mean dosage 74 (SD 4) micrograms/kg/min for 0‐20 minutes and 51 (SD 7) micrograms/kg/min for 20‐40 minutes)
Study: 1233261
Drug: MK‐356 (525
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐356 (525 mg)
Study: 1233261
Drug: MK‐356 (2100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐356 (2100 or 1050 mg)
Study: 1233261
Drug: MK‐356 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐356 (400 mg probenecid coadministered with 700 mg pivampicillin)
Study: 1233261
Drug: Pivampicillin (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin (350 mg)
Study: 26055239
Drug: 30-min daily
Normalized name: lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30-min daily exercise intervention (standing, upright exercise regimen)
Study: 18719924
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy (BFB)
Study: 18719924
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin A (BTX-A) injection
Study: 15061154
Drug: Sertraline, Bupropion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline, Bupropion, Venlafaxine, Cognitive Therapy (level 2 switch options)
Study: 15061154
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy (level 2 augment option)
Study: 15061154
Drug: Lithium, Thyroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium, Thyroid Hormone (level 3 augment options)
Study: 15061154
Drug: Tranylcypromine, Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranylcypromine, Combination of Mirtazapine and Venlafaxine (level 4 switch options)
Study: 23780807
Drug: Cholesterol-lowering medications
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering medications (including statins)
Study: 23780807
Drug: Cholesterol-lowering medications
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering medications (after 2002)
Study: 23780807
Drug: Cholesterol-lowering medications
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering medications (trend after 2002)
Study: 16007328
Drug: Neridronate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neridronate therapy with calcium + vitamin D
Study: 12824258
Drug: Adenosine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (40 microg/kg per minute, 30 minutes per infusion step)
Study: 10468312
Drug: Tiapride 100
Normalized name: tiapride 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride 100 mg
Study: 324417
Drug: Intraoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative antibiotic wound lavage
Study: 324417
Drug: Antibiotic solution
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic solution irrigation
Study: 324417
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic wound lavage
Study: 25482832
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg orally daily for 24 weeks
Study: 23332288
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2) plus carboplatin (AUC 6)
Study: 8020529
Drug: Asiatic acid
Normalized name: Asiatic Acid
DrugBank: Asiatic acid (DB14054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asiatic acid (12 mg)
Study: 8020529
Drug: Asiaticoside (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asiaticoside (24 mg)
Study: 18279476
Drug: Dextromethorphan 22
Normalized name: guaifenesin/dextromethorphan 225 mg-25 mg/5 mL ORAL SOLUTION, ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 22 mg 0.8 ml(‐1)
Study: 12469157
Drug: 10(6) units
Normalized name: reteplase 10 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(6) units of macrophage colony-stimulating factor (low dose group)
Study: 12469157
Drug: 8x10(6) units
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8x10(6) units of macrophage colony-stimulating factor (high dose group)
Study: 1815717
Drug: Prema Compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prema Compound
Study: 6511154
Drug: Androgenic steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgenic steroids (average 45 mg/day) during an 8-week strength training period
Study: 27215279
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg recombinant HepB vaccine
Study: 27215279
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg recombinant HepB vaccine
Study: 27215279
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg recombinant HepB vaccine (adults)
Study: 27215279
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg recombinant HepB vaccine (adults ages 15-24)
Study: 27215279
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage of HepB vaccine (adults ages 25 and older)
Study: 23281382
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of lamivudine (LAM) 100 mg/d plus adefovir dipivoxyl (ADV) 10 mg/d
Study: 23281382
Drug: Adefovir dipivoxyl
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxyl (ADV) 10 mg/d
Study: 23281382
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of lamivudine (LAM) and adefovir dipivoxyl (ADV)
Study: 20179232
Drug: Hydrogen sulfate
Normalized name: XYLAN, HYDROGEN SULFATE
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen sulfate (Hyd-Sulfate) capsule of AZD6244 (75 mg twice daily)